Sunday, July 28, 2013 2:20:54 PM
you along with reviewing information and agreements you provided.
Hillard Herzog, CEO
Bergamo Acquisition Corp
Dear Mr. Herzog;
Included you will find the compiled financial statements of Bergamo Acquisition Corp as of and for the
period ended September 17, 2012. The financial statements were prepared based on discussions with
you along with reviewing information and agreements you provided. Thanks for giving us the
opportunity to serve Bergamo Acquisition Corporation. We look forward to working together in the
future.
Sincerely,
L.L. Bradford & Company, LLC
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92173
THE INDEPENDENT ACCOUNTING FIRM OF L.L.BRADFORD WOULD NOT RISK THEIR BUSINESS LICENCE FOR HERZOG OR ANYONE ELSE BY PRODUCING A COMPILED FINANCIAL THAT IS ERRONEOUS OR MISLEADING
THERE IS THE PROOF BGMO HAS THE $88 MILLION AND MORE TO COME $$$$$$$$$
Bradford`s disclaimers in the cover letter does not give them legal right to produce a financial statement that is false or misleading
http://www.bullivant.com/Accountants-risks-presented-in-the-preparation
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Compiled financial statements, also referred to as unaudited statements, are not audited adequately and no opinion on the quality of the financial statements is given. Statements and guarantees about the accuracy of the financial statements are much less than that given by certified financial statements. Accountants that compile a company's financial statements are not required to verify or confirm the records and they do not need to analyze the statements for accuracy. However, in the event that an accountant finds erroneous, misleading or incomplete information in the financial statements they must notify management or abandon their involvement in assessing the company’s financial statements. The accountant who is appointed to compile a company’s financial statement must be familiar with the company and its main business processes.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM